| Type 2 Diabetes Mellitus |
1 |
1 |
| Cerebrovascular Accident |
0 |
0.9 |
| Insulin Resistance |
0 |
0.94 |
| Thromboembolism |
0 |
0.66 |
| Hypertension |
0 |
0.63 |
| Hemorrhagic Stroke |
0 |
0.17 |
| Stroke Risk |
0 |
0.99 |
| Body Mass Index |
0 |
0.11 |
| Ischemic Stroke |
0 |
0.11 |
| Health Insurance |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.07 |
| Cerebrovascular Accident History |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Hemoglobin |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Insurance |
0 |
0.06 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.06 |
| Pharmacogenomics |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Residency |
0 |
0.06 |
| Genomic Medicine |
0 |
0.05 |
| Type 1 Diabetes Mellitus |
0 |
0.03 |